Lantheus acquires Cerveau Technologies, adding Alzheimer's Tau PET imaging agent MK-6240

Lantheus Holdings, Inc.

Acquired Cerveau Technologies, gaining MK-6240, an F18-labeled PET imaging agent targeting Tau tangles in Alzheimer's disease.
MK-6240 is currently used in over 60 academic and industry clinical trials by more than 16 pharmaceutical companies.
Terms include upfront payment plus development and commercial milestone payments, with double-digit royalties on research revenue and commercial sales.
Transaction structured as a stock purchase; seller to provide transition and clinical development services post-closing.
Lantheus expects to expand its radiopharmaceutical diagnostic imaging pipeline into Alzheimer's disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.